"Intravitreal Injections" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The administration of substances into the VITREOUS BODY of the eye with a hypodermic syringe.
| Descriptor ID |
D058449
|
| MeSH Number(s) |
E02.319.267.530.475.500
|
| Concept/Terms |
Intravitreal Injections- Intravitreal Injections
- Injection, Intravitreal
- Injections, Intravitreal
- Intravitreal Injection
|
Below are MeSH descriptors whose meaning is more general than "Intravitreal Injections".
Below are MeSH descriptors whose meaning is more specific than "Intravitreal Injections".
This graph shows the total number of publications written about "Intravitreal Injections" by people in this website by year, and whether "Intravitreal Injections" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 7 | 7 |
| 2012 | 0 | 8 | 8 |
| 2013 | 3 | 7 | 10 |
| 2014 | 1 | 11 | 12 |
| 2015 | 2 | 23 | 25 |
| 2016 | 2 | 8 | 10 |
| 2017 | 3 | 4 | 7 |
| 2018 | 1 | 17 | 18 |
| 2019 | 1 | 25 | 26 |
| 2020 | 3 | 23 | 26 |
| 2021 | 0 | 19 | 19 |
| 2022 | 0 | 11 | 11 |
| 2023 | 1 | 7 | 8 |
| 2024 | 13 | 12 | 25 |
| 2025 | 2 | 4 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Intravitreal Injections" by people in Profiles.
-
Magrath G, Luvisi J, Russakoff D, Oakley J, Say EA, Blice J, Jayagopal A, Tucker S, Loayza A, Baker GH, Obeid JS. Use of a Convolutional Neural Network to Predict the Response of Diabetic Macular Edema to Intravitreal Anti-VEGF Treatment: A Pilot Study. Am J Ophthalmol. 2025 May; 273:176-181.
-
Kalavar M, Sridhar J. Clinical trials and real-world studies examining faricimab and high-dose aflibercept for wet age-related macular degeneration and diabetic macular edema. Curr Opin Ophthalmol. 2025 May 01; 36(3):189-198.
-
Durrani AF, Chaudhary V, Garg SJ. Reducing rates of endophthalmitis from intravitreal injections - strategies and areas of controversy. Curr Opin Ophthalmol. 2025 May 01; 36(3):229-236.
-
Zhao CS, Chwialkowski K, Wai KM, Mruthyunjaya P, Rahimy E, Koo EB. Risk of Cataract Surgery Complications in Patients With Prior Intravitreal Injection Therapy. Am J Ophthalmol. 2025 04; 272:106-116.
-
Shields CL, Medina R, Evans H, Valdes-Perez N, Acar AB, Bansal R, Lally SE, Shields JA. HIGH-DOSE INTRAVITREAL TOPOTECAN FOR RECURRENT RETINOBLASTOMA, SUBRETINAL SEEDS, AND VITREOUS SEEDS. Retina. 2025 01 01; 45(1):1-6.
-
Momenaei B, Yonekawa Y, Abril P, McCullough R, Abbey AM. Outcomes of Intravitreal Aflibercept 8 mg in Eyes With Neovascular Age-Related Macular Degeneration Previously Treated With Faricimab. Ophthalmic Surg Lasers Imaging Retina. 2025 04; 56(4):206-211.
-
Swaminathan S, Mahmoudzadeh R, Wakabayashi T, Bowers M, Momenaei B, Abishek RM, Salabati M, Hsu J, Dunn JP. OUTCOMES OF PRO RE NATA VERSUS TREAT-AND-EXTEND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS FOR MYOPIC MACULAR NEOVASCULARIZATION IN MULTIETHNIC PATIENTS IN THE UNITED STATES. Retina. 2024 12 01; 44(12):2057-2065.
-
Gonzales J, Acharya NR, Sugar EA, Burke AE, Vitale AT, Gupta V, Dunn JP, Lightman SL, Thorne JE, Kim RY, Yeh S, Altaweel MM, Kempen JH, Holbrook JT, Jabs DA. Macular Edema Ranibizumab versus Intravitreal Anti-inflammatory Therapy Trial: 24-Week Outcomes of Uveitic Macular Edema Re-treatment. Ophthalmology. 2025 May; 132(5):527-537.
-
Kaufmann GT, Boucher N, Sharma C, Aggarwal N, Starr MR. Submacular Hemorrhage Rates Following Anti-Vascular Endothelial Growth Factor Injections for Exudative Age-Related Macular Degeneration. Am J Ophthalmol. 2025 Feb; 270:172-182.
-
Nahar A, Eliott D, Avery RL, Pulido J, Eagle RC, Carrasco JR, Crawford C, Milman T, Stagner AM. Retinal Vasculopathy and Choroiditis after Pegcetacoplan Injection: Clinicopathologic Support for a Drug Hypersensitivity Reaction. Ophthalmol Retina. 2025 04; 9(4):352-366.